SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(McIlleron Helen M.)
 

Sökning: WFRF:(McIlleron Helen M.) > (2008-2009) > Population Pharmaco...

Population Pharmacokinetics of Rifampin in Pulmonary Tuberculosis Patients Including a Semi-mechanistic Model to Describe Variable Absorption

Wilkins, Justin J. (författare)
Uppsala universitet,Institutionen för farmaceutisk biovetenskap
Savic, Radojka M. (författare)
Uppsala universitet,Institutionen för farmaceutisk biovetenskap
Karlsson, Mats O. (författare)
Uppsala universitet,Institutionen för farmaceutisk biovetenskap
visa fler...
Langdon, Grant (författare)
McIlleron, Helen (författare)
Pilai, Goonaseelan (författare)
Smith, Peter (författare)
Simonsson, Ulrika (författare)
Uppsala universitet,Institutionen för farmaceutisk biovetenskap,farmakometri
visa färre...
 (creator_code:org_t)
2008
2008
Engelska.
Ingår i: Antimicrobial Agents and Chemotherapy. - 0066-4804 .- 1098-6596. ; 52:6, s. 2138-2148
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • This article describes the population pharmacokinetics of rifampin in South African pulmonary tuberculosis patients. Three datasets containing 2,913 rifampin plasma concentration-time data points, collected from 261 South African pulmonary tuberculosis patients aged 18 to 72 years and weighing 28.5 to 85.5 kg and receiving regular daily treatment that included administration of rifampin (450 to 600 mg) for at least 10 days, were pooled. A compartmental pharmacokinetic model was developed using nonlinear mixed-effects modeling. Variability in the shape of the absorption curve was described using a flexible transit compartment model, in which a delay in the onset of absorption and a gradually changing absorption rate were modeled as the passage of drug through a chain of hypothetical compartments, ultimately reaching the absorption compartment. A previously described implementation was extended to allow its application to multiple-dosing data. The typical population estimate of oral clearance was 19.2 liters . h(-1), while the volume of distribution was estimated to be 53.2 liters. Interindividual variability was estimated to be 52.8% for clearance and 43.4% for volume of distribution. Interoccasional variability was estimated for CL/F (22.5%) and mean transit time during absorption (67.9%). The use of single-drug formulations was found to increase both the mean transit time (by 104%) and clearance (by 23.6%) relative to fixed-dose-combination use. A strong correlation between clearance and volume of distribution suggested substantial variability in bioavailability, which could have clinical implications, given the dependence of treatment effectiveness on exposure. The final model successfully described rifampin pharmacokinetics in the population studied and is suitable for simulation in this context.

Nyckelord

PHARMACY
FARMACI

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy